Compelling Data on Mazor Robotics’ PROlif Lateral Solution Presented at Society for Minimally Invasive Spine Surgery Global...
November 10 2015 - 04:30AM
Business Wire
- Recently introduced lateral solution
garnering positive interest from surgeons and hospital
administrators -
- Anticipated to reduce operating room (OR)
time by up to one hour -
Mazor Robotics, Ltd. (TASE:MZOR; NASDAQ GM:MZOR), a developer of
innovative surgical guidance systems and complementary products,
announces the first presentation of data for Mazor’s PROlif™
Lateral solution, and the first time the procedure was shown on a
cadaver at a medical conference. Both occurred last week during the
Society for Minimally Invasive Spine Surgery (SMISS) Global Forum
’15 in Las Vegas.
A podium presentation entitled, Comparison Of Fluoro-guided vs.
Robotic-guided Single-position Lateral Interbody Fusion and
Posterior Fixation—A Preliminary Report, reported fluoroscopy time
per screw was reduced by approximately one-third when Mazor
Robotics technology was used. Neurosurgeon J. Alex Thomas, MD also
reported zero revisions in those cases compared to three revisions
in the fluoro-guided group.
In addition to the clinical data presented, SMISS Co-Chairman
Kornelis Poelstra, MD, PhD, also led a Cadaver Workshop to
demonstrate that PROlif is the only true single position solution
for circumferential spinal fusion by using the Renaissance system
to place pedicle screws in the lateral decubitus position.
“The Renaissance Guidance System easily integrates into my
existing operating workflow and when using PROlif, it saves 45-60
minutes of anesthesia- and surgical time per case,” said Dr.
Poelstra. “This improved efficiency means for us a clinically
significant reduction in complication risk, in addition to the
economic benefits for our institution. It typically amounts to
enough time savings over two cases that I can perform an additional
surgery that same day without ever compromising patient
outcomes.”
“The interest we have seen in our PROlif Lateral solution
illustrates that it is quickly gaining momentum and its value is
being seen by many in the industry,” said Ori Hadomi, Chief
Executive Officer of Mazor Robotics. “Mazor’s mission to heal
through innovation is being realized when we introduce new
solutions that improve both the patient and surgeon experience, as
Dr. Poelstra has stated.”
PROlif™ Lateral is a solution to enable the guided placement of
pedicle screws while the patient is in lateral decubitus position
to reduce OR time by eliminating the need to flip the patient into
prone position after an extreme lateral procedure.
About Mazor
Mazor Robotics (TASE:MZOR; NASDAQGM:MZOR) believes in healing
through innovation by developing and introducing revolutionary
robotic-based technology and products aimed at redefining the gold
standard of quality care. Mazor Robotics Renaissance® Guidance
System enables surgeons to conduct spine and brain procedures in a
more accurate and secure manner. For more information, please visit
www.MazorRobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other securities laws. Any statements in this release about
future expectations, plans or prospects for the Company, including
without limitation, statements regarding the interest in the
Company’s PROlif Lateral solution and its benefits, and other
statements containing the words “believes,” “anticipates,” “plans,”
“expects,” “will” and similar expressions are forward-looking
statements. These statements are only predictions based on Mazor's
current expectations and projections about future events. There are
important factors that could cause Mazor's actual results, level of
activity, performance or achievements to differ materially from the
results, level of activity, performance or achievements expressed
or implied by the forward-looking statements. Those factors
include, but are not limited to, the impact of general economic
conditions, competitive products, product demand and market
acceptance risks, reliance on key strategic alliances, fluctuations
in operating results, and other factors indicated in Mazor's
filings with the Securities and Exchange Commission (SEC) including
those discussed under the heading "Risk Factors" in Mazor’s annual
report on Form 20-F filed with the SEC on April 29, 2015 and in
subsequent filings with the SEC. For more details, refer to Mazor's
SEC filings. Mazor undertakes no obligation to update
forward-looking statements to reflect subsequent occurring events
or circumstances, or to changes in our expectations, except as may
be required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151110005422/en/
U.S. Contacts: EVC GroupInvestorsMichael Polyviou,
212-850-6020mpolyviou@evcgroup.comDoug Sherk,
646-445-4800dsherk@evcgroup.comorMediaDavid Schemelia,
646-201-5431dave@evcgroup.com
Mazor Robotics (NASDAQ:MZOR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Mazor Robotics (NASDAQ:MZOR)
Historical Stock Chart
From Mar 2023 to Mar 2024